Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
about
Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published LiteratureHaploidentical Transplantation in Children with Acute Leukemia: The Unresolved IssuesHaploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic DisordersModern approaches to HLA-haploidentical blood or marrow transplantationPost-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantationCurrent and emerging strategies for the prevention of graft-versus-host diseaseHaploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular TherapyHigh-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies.High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantationTransplantation tolerance: from theory to clinic.Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamideNovel regulatory therapies for prevention of Graft-versus-host disease.Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcomeNovel therapeutics for the treatment of graft-versus-host disease.Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.High-dose cyclophosphamide for graft-versus-host disease prevention.Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamideNonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamideImmune Reconstitution Kinetics following Intentionally Induced Mixed Chimerism by Nonmyeloablative Transplantation.Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model.Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftmentReduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.Blockade of individual Notch ligands and receptors controls graft-versus-host diseaseEvolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance.Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia.Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationPerivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantationPost-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.
P2860
Q26749454-327CA3FB-8464-4A4D-8DDB-701DD5A66D38Q26750671-2A6F9D13-0C37-4CDE-B2AC-218F2AFF9FA0Q26767501-525D619C-0343-4AF8-A720-76A44A349A63Q26797506-747DE143-3331-4780-9484-8E4186D8619AQ26852474-D37C1D3D-7396-49B0-8F8C-3C6DB7B5F70EQ27016541-435CCF16-F50F-496E-8467-CC93B84CB839Q28085397-476C7D96-EDF1-49A2-9478-886A9437A923Q33806054-C128824C-E97B-4CFF-B554-986192E51553Q33856960-B510CBAA-67AB-488F-AAD5-E358FEF85ABCQ33941128-F87A81A9-BD97-497D-A5DD-61C8C88FF7D9Q34082059-7271D33A-062D-4961-8B5F-66654BA00FEBQ34138598-F19E5938-6AD4-437D-AA73-4CA5CC307F17Q34269481-70A596BE-C630-4A9E-B9E8-5420A97E446EQ34293038-131CE717-30FB-455E-A23F-597F9CF4782AQ34388640-DD7E2408-0F26-42F2-95FE-B1DD3A677D9EQ34841838-A6F38DB0-E2DC-4961-946A-74D4DA540171Q35060682-62D0D6DE-1E8C-412E-B3C5-2B1500998F5AQ35110765-5834B35F-50A2-42D2-A37B-1EAA1179595BQ35112222-4C1A5C7F-3C68-4BE5-93BD-0E9A87840403Q35129248-0BDDF691-DFF4-47C6-99AB-C1563B26B2B4Q35478934-852BF09A-F3B0-4001-98D8-DF240FB819B1Q35505839-4BF0B679-57A9-419D-90EF-67054F169A18Q35626689-99DF7935-3E80-42AE-B9CF-8057C520E62CQ35828638-681EE440-804B-44A2-808C-F604381CE3CAQ35976578-149ECDE0-2BF4-4625-AE74-A1A7D0CA745EQ36253363-7323A97B-ED88-4DB7-8268-1C4B277835B8Q36286127-797D6C7F-E37E-4032-A72C-BF15386AFAE1Q36425417-9958D311-E39D-4DA4-BB35-26C39D6182FCQ36433025-E9229A7A-A70B-445D-941B-65C7640EB3F9Q36445665-551C4E0E-8F12-4F5B-B147-8B18B1099E19Q36488985-E00AC8FD-5D9E-4B90-A6C5-FB87B1BFE8B5Q36596897-39CA585F-BA9B-4331-B5D6-7619FD4AF763Q36724916-0629D1EE-B1A5-49B5-96A3-A37206D00734Q36733439-461ED812-A9E4-445D-A722-6CBF66AC7027Q36752218-CF5E791D-6C70-4D8B-8A1E-F403F8BDB2D5Q36754109-50E38BB6-413E-4ACA-B4CC-9F6666189AE4Q36814661-335E7841-157B-4B5D-96CB-E2649C29A54FQ36891433-4155EFA3-3AD2-498A-B838-308685A811A1Q36997172-B2D16BDA-84C7-4DB0-9158-3AA991FDA320Q37029856-7670C570-77D6-48A6-8033-7C3E769A4785
P2860
Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Durable engraftment of major h ...... nsplantation cyclophosphamide.
@en
Durable engraftment of major h ...... nsplantation cyclophosphamide.
@nl
type
label
Durable engraftment of major h ...... nsplantation cyclophosphamide.
@en
Durable engraftment of major h ...... nsplantation cyclophosphamide.
@nl
prefLabel
Durable engraftment of major h ...... nsplantation cyclophosphamide.
@en
Durable engraftment of major h ...... nsplantation cyclophosphamide.
@nl
P2093
P1433
P1476
Durable engraftment of major h ...... nsplantation cyclophosphamide.
@en
P2093
P304
P356
10.1182/BLOOD.V98.12.3456
P407
P577
2001-12-01T00:00:00Z